MARKET TALK: Glaxo Gradually Returning To Growth - Ambrian

26th Jul 2010 11:56

1056 GMT [Dow Jones] Ambrian analyst Mike Ward says he retains a buy on GlaxoSmithKline (GSK) after 2Q results showed benefits of an increasingly diversified business whose strong pipeline has delivered a further five Phase III candidates. Says drug maker "is gradually returning to growth after a period of high generic sales attrition, which is now almost over ... GSK combines improving growth prospects with high yield." Shares -2.2% at 1161p. ([email protected]) Contact us in London. +44-20-7842-9464 [email protected] (END) Dow Jones Newswires July 26, 2010 06:56 ET (10:56 GMT)

Top Risers

Share	Price	Change
Huddled Group (HUD)	0.85	24.14%
Eurasia Mining (EUA)	2.80	19.15%
Genincode (GENI)	0.725	16%
Medpal AI (MPAL)	5.25	14.13%
Light Science Technologies (LST)	0.875	12.9%

Top Fallers

Share	Price	Change
Catenai Plc (CTAI)	0.0575	-39.47%
Petra Diamonds (PDL)	2.60	-26.14%
Focus Xplore (FOX)	0.019	-22.45%
Litigation Cap. (LIT)	0.301	-20.12%
Abrdn Property (API)	1.52	-15.56%

Top By Volume

Share	Price	Volume
Ethernity Net (ENET)	0.0019	1,922,336,250
Forgent (FORG)	0.0115	591,087,829
Premier African Minerals (PREM)	0.0044	313,776,718
Focus Xplore (FOX)	0.019	253,421,870
Bezant Resources PLC (BZT)	0.11	246,929,868

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.